Inhibition of P210BCR/ABL Expression in K562 Cells by Electroporation with an Antisense Oligonucleotide

Taj, Abid Sohail; Martiat, Philippe; Dhut, Susheela; Chaplin, Tracy; Dowding, C; Th'ng, K. H.; Goldstein, Ido; Daley, GQ; Young, BD; Goldman, John M.

doi:10.3109/10428199009050996

Cited by 20 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…De Fabritiis et al [16], Skorski et al [17] and Szczylik et al [18] used phosphodiester oligodeoxynucleotides against the two possible BCR-ABL junctions in CML and found a significant spe cific suppression of clonogenic growth in a colony assay. Others [15] were able to suppress p210BCR_ABL kinase activity in K562 cells by electroporation of antisense oli godeoxynucleotides against the very first 5' sequences of the BCR-ABL gene, but not with oligos against the junc tion sites in CML.…”

Section: Discussionmentioning

confidence: 99%

“…Several study groups have tried to suppress BCR-ABL gene activity both in established cell lines (e.g. K562, BV-173) and in primary CML cells from patients in chronic phase and in blast crisis [14,15]. De Fabritiis et al [16], Skorski et al [17] and Szczylik et al [18] used phosphodiester oligodeoxynucleotides against the two possible BCR-ABL junctions in CML and found a significant spe cific suppression of clonogenic growth in a colony assay.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Unmodified Phosphodiester Antisense Oligodeoxynucleotides to the BCR-ABL Junction Do Not Suppress Philadelphia-Positive Clonogenic Cells

Kabisch

Pérènyi²,

Seay³

et al. 1994

Acta Haematol

View full text Add to dashboard Cite

The BCR-ABL fusion gene is directly involved in the pathogenesis of chronic myeloid leukemia (CML). Specific inhibition of the BCR-ABL gene expression with antisense oligodeoxynucleotides has been shown to have profound effects on cell growth in vitro. We examined antisense phosphodiester oligonucleotides (16-mers at a concentration of 60 μg/ml) spanning the two possible junction sites K28 (b3a2) and L6 (b2a2) in a clonogenic assay. Single colonies from 9 patients with CML and from patients with normal bone marrow were screened for BCR-ABL expression with a new ‘single-tube nested PCR’ method. There was a marked reduction in colony number in the CML group and a lesser growth inhibition in the control group. The number and percentage of BCR-ABL-positive colonies, however, was not reduced in the CML group. This indicates a nonspecific growth inhibition only.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Unmodified Phosphodiester Antisense Oligodeoxynucleotides to the BCR-ABL Junction Do Not Suppress Philadelphia-Positive Clonogenic Cells

Kabisch

Pérènyi²,

Seay³

et al. 1994

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…Reference (Rosti et al, 1992) (Patinkin et al, 1994) (Abubakr et al, 1994) (Campos et al, 1994) (Keith et aI., 1995) (Kitada et al, 1993) (Ryte et aI., 1993) (Webb et al, 1996) (McGahon et al, 1994) (Taj et al, 1990) (Bedi et al, 1994) (de Fabritiis etal., 1993, 1994, 1995a) (Maekawa et al, 1995) (Giles et al, 1995a) (Kabisch et al, 1994) (Kirkland et al, 1993) (Mahon et al, 1993) (Marti at et al, 1993 (O'Brien et al, 1994) (Skorski et al, 1993) (Skorski et al, 1994b) (Skorski et al, 1994a) (Skorski et al, 1995) (Smetsers et al, 1994 Smetsers and Mensink, 1995) (Tari et al, 1994) (Vaerman et al, 1995) (Yao and Scott, 1993) (Fournier et al, 1994) (Sparatore et al, 1993) (Nguyen et al, 1993) (Rogers et al, 1994) (Takeshita et al, 1993) (Kobayashi et al, 1993) Reference (Kato et ai., 1994) (Louie et ai., 1993) (Barut et al, 1993) (Schulter et al, 1993) (Scheuermann et al, 1994) (Azuma et ai., 1994) ) (Kizaki et al, 1993) (Methia et al, 1993) (Anfossi et al,...…”

Section: Chaptermentioning

confidence: 99%

Blood Cell Biochemistry

Fairbairn¹,

Testa²

1999

Blood Cell Biochemistry

View full text Add to dashboard Cite

show abstract

“…In the last few years, different authors have described potentially fruitful approaches toward selective growth inhibition of Philadelphia-positive leukemic cells by antisense molecules [ 10,11,[13][14][15]19,16]. These experiments have been performed using various experimental conditions: cell lines in culture, fresh CML cells in culture, and animal models.…”

Section: Antisense Oligonucleotidesmentioning

confidence: 99%

Antisense inhibition of P210bcr&hyphen;ablin chronic myeloid leukemia

1993

Self Cite

View full text Add to dashboard Cite

Abstract. The evidence that the bcr-ubl gene product (P210) of the Philadelphia chromosome plays a crucial role in the pathogenesis of chronic myeloid leukemia (CML), and the absence of the bcr-abl fused transcript in non-malignant cells makes this messenger RNA an ideal candidate for antisense strategies in CML. To inhibit the expression of the bcr-abl gene, and to try to eradicate Philadelphiapositive cells, Merent methods can be used: 1) the introduction into the cells of antisense oligonucleotides, 2) the use of specfie ribozymes, or 3) the transduction, using retroviral vectors, of stably integrated sequences coding for antisense RNA.Each of these approaches has potential advantages and drawbacks that are discussed below. Although many data emerge that support the use of anti-bcr-lrbl antisense molecules in CML, numerous questions remain to be completely answered before the most efficient strategy can be designed, either for in vitro or in vivo purposes.

show abstract

Inhibition of P210BCR/ABL Expression in K562 Cells by Electroporation with an Antisense Oligonucleotide

Cited by 20 publications

References 19 publications

Unmodified Phosphodiester Antisense Oligodeoxynucleotides to the BCR-ABL Junction Do Not Suppress Philadelphia-Positive Clonogenic Cells

Unmodified Phosphodiester Antisense Oligodeoxynucleotides to the BCR-ABL Junction Do Not Suppress Philadelphia-Positive Clonogenic Cells

Blood Cell Biochemistry

Antisense inhibition of P210bcr&hyphen;ablin chronic myeloid leukemia

Contact Info

Product

Resources

About